Risperidone and aripiprazole are US Food and Drug Administration (FDA)–approved to treat irritability and aggression in autism spectrum disorder. This is a time to reflect on whether the terminology of these medications is respectful to this patient population. Misleading terminology can give rise to uncertainty and delay in treatment. Based on past examples of evolving medication nomenclature, we advocate for a change in the language used to describe these medications to improve clarity surrounding treatment and support inclusive and positive care experiences.
KannerL. Autistic disturbances of affective contact. Nervous Child. 1943;2(4):217–250.
2.
GoltJKanaRK. History of autism. In: KanaRK, ed. The Neuroscience of Autism. Elsevier Inc.; 2022:1-14.
3.
VolkmarFRMcPartlandJC. From Kanner to DSM-5: autism as an evolving diagnostic concept. Annu Rev Clin Psychol.2014;10(1):193-212. doi:10.1146/annurev-clinpsy-032813-153710
4.
CampbellMGellerBCohenIL. Current status of drug research and treatment with autistic children. J Pediatr Psychol.1977;2(4):153-161. doi:10.1093/jpepsy/2.4.153
5.
CohenILCampbellMPosnerDSmallAMTriebelDAndersonLT. Behavioral effects of haloperidol in young autistic children: an objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry.1980;19(4):665-677. doi:10.1016/s0002-7138(09)60969-9
6.
PoseyDJStiglerKAEricksonCAMcDougleCJ. Antipsychotics in the treatment of autism. J Clin Invest.2008;118(1):6-14. doi:10.1172/jci32483
7.
McDougleCJHolmesJPCarlsonDCPeltonGHCohenDJPriceLH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry.1998;55(7):633-641. doi:10.1001/archpsyc.55.7.633
8.
McCrackenJTMcGoughJShahB, et al.Risperidone in children with autism and serious behavioral problems. N Engl J Med.2002;347(5):314-321. doi:10.1056/nejmoa013171
9.
BlankenshipKEricksonCAStiglerKAPoseyDJMcDougleCJ. Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years. Ped Health.2010;4(4):375-381. doi:10.2217/phe.10.45
10.
XiongW. Pediatric pharmacologic management of autism-associated behavioral dysregulation. Am J Psychiatry Resid J. 2017;12(9):3-5. doi:10.1176/appi.ajp-rj.2017.120902
11.
DenikerP. From chlorpromazine to tardive dyskinesia (brief history of the neuroleptics). Psychiatr J Univ Ottawa. 1989;14(1):253-259.
12.
CaldwellA. Origins of psychopharmacology: from CPZ to LSD. Charles C. Thomas; 1970:150-152.
13.
KingCVorugantiLN. What's in a name? The evolution of the nomenclature of antipsychotic drugs. J Psychiatry Neurosci. 2002;27(3):168-175.
14.
SajatovicMJenkinsJH. Is antipsychotic medication stigmatizing for people with mental illness?Int Rev Psychiatry.2007;19(2):107-112. doi:10.1080/09540260701278911
15.
TandonRLenderkingWRWeissC, et al.The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey. Ann Gen Psychiatry. 2020;19(1):42. Published 2020 Jul 13. doi:https://doi.org/10.1186/s12991-020-00292-5.
16.
MattinglyGMatthews-HayesTPatelMDKramerKStahlSM. Do we need a new nomenclature for atypical antipsychotics? A survey of health care professionals and patients. Prim Care Companion CNS Disord. 2023;25(1):22m03331. Published 2023 Feb 23. doi:10.4088/PCC.22m03331.
17.
TemkinNR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia. 2001;42(4):515-524. doi:10.1046/j.1528-1157.2001.28900.x
18.
FrenchJAPeruccaE. Time to start calling things by their own names? The case for antiseizure medicines. Epilepsy Curr. 2020;20(2):69-72. doi:10.1177/1535759720905516
19.
BhallaDRossSLoftalinezhadE, et al.Antiepileptic drugs: is terminology appropriate? A change might be needed. Neurol Asia.2015;20(2):117.
20.
PeruccaEFrenchJAAljandeelG, et al.Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper. Epilepsia. 2024;65(3):533-541. doi:10.1111/epi.17877
